weekly. The primary endpoint was overall survival, and the median follow-up was 5.5 years. The 5-year overall survival was 58.6% (95% confi dence interval [CI] = 50.9% to 66.2%) for the RT arm and 70.3% (95% CI = 63.4% to 77.3%) for the CRT arm. In Cox regression analysis adjusted for T stage, age, and overall stage, the difference in overall survival was statistically signifi cantly in favor of concurrent CRT ( P = The mainstay treatment for nasopharyngeal carcinoma (NPC) has been radiotherapy ( 1 ) . Despite encouraging response rates to chemotherapy, randomized studies of neoadjuvant and/or adjuvant chemotherapy have not shown an improvement in overall survival (OS) ( 2 -7 ) . The United States Intergroup conducted a study demonstrating superior OS using concurrent cisplatin 100 mg/ m 2 D1 every 3 weeks for three cycles during radiotherapy followed by adjuvant cisplatin 80 mg/m 2 D1, 5-fluorouracil 1 g/m 2 D1 -4 every 4 weeks for three cycles ( 8 ) . However, the poor results of the radiotherapy-alone arm, the relatively high percentage of squamous cell carcinoma, and the poor compliance to adjuvant chemotherapy emphasized the need for confi rmatory studies, particularly in endemic populations. Lin et al. ( 9 ) randomly assigned 284 patients to concurrent chemotherapy -radiotherapy using infusional cisplatin and 5-fl uorouracil, demonstrating a positive effect on OS. However, the general applicability of infusional therapy is limited. This is an updated fi nal report on OS of the previously published progressionfree survival (PFS) analysis of a phase III randomized study addressing whether adding cisplatin concurrently to radiotherapy improves survival compared with radiotherapy alone in locally advanced NPC ( 10 ) . Patients with Ho's N2-or N3-stage or N1-stage with node size of at least 4 cm ( 11 ) were eligible for this trial, and patients were also classifi ed according to the 1997 International Union Against Cancer (UICC) staging system ( 12 ) ( Table 1 ). The protocol was approved by the institutional review boards of Prince of Wales Hospital (PWH) and Queen Elizabeth Hospital (QEH), and all patients gave written informed consent. Patients were stratifi ed by center and randomly assigned to concurrent cisplatinradiotherapy or radiotherapy alone. The external radiotherapy technique (ERT) of the two institutions has been published previously ( 10 ) . The nasopharynx was treated to 66 Gy in 33 fractions per 6.5 weeks; parapharyngeal boost was given to patients with parapharyngeal involvement to 20 Gy in 10 fractions in 2 weeks (PWH) and 10 Gy in fi ve fractions in 1 week (QEH). Patients with any palpable residual nodes after ERT were treated with 7.5 Gy in two fractions in 4 days. Patients with biopsy-proven persistent local disease were given intracavitary brachytherapy using iridium-192 sources to 24 Gy in three fractions in 15 days (PWH) and 21 Gy in three fractions in 15 days (QEH). The parapharyngeal boost and brachytherapy doses refl ect the standard local practice of PWH and QEH, with no published data of impact on treatment outcome. Patients randomly assigned to the chemotherapy -radiotherapy arm received cisplatin 40 mg/m 2 in 1 L of normal saline over 2 hours weekly during ERT ( 10 ) . Patients were seen every 8 weeks in the fi rst year, every 12 weeks in the second and third years, and every 16 -24 weeks thereafter. At each followup visit, patients would undergo history and physical examination, routine mirror or endoscopic examination of the nasopharynx, and tests for distant failure if clinical suspicion existed.
OS is defi ned as the time from randomization to the time of death or last followup, analyzed by the Kaplan -Meier method. The log-rank test was used to assess the difference in survival between treatment groups. Cox regression modeling was used to assess and control for statistically signifi cant prognostic factors and included adjustments for center, age, sex, histology, and stage. The proportional hazards assumption was verifi ed by both log-minus-log survival plots and time-dependent variable method based on the Cox model. For the primary analysis, adjustments for statistically signifi cant prognostic factors were performed. All other exploratory analyses on the treatment effect within subgroups were unadjusted. A test of treatment-by-covariate interaction for the fi nal Cox model was carried out. Time to local recurrence or distant metastasis was defi ned from time of random assignment to the time of local recurrence or distant metastasis or censored at last follow-up. All statistical tests were two-tailed, and P< .05 was considered statistically signifi cant.
Eight patients who were randomly assigned to the chemotherapy -radiotherapy arm who received no chemotherapy were included in the analysis according to the intention-to-treat principle ( Fig. 1 ) . All patients were evaluated for treatment toxicity, disease control, and PFS. Ten patients were lost to follow-up and were censored in the OS analysis. The treatment details and response, toxicity, and PFS analysis after 108 events had occurred have been published previously. Although systemic toxicity was more frequent in the CRT arm, 78% of patients completed at least four cycles of concurrent cisplatin during radiotherapy, and there were no treatment-related deaths ( 10 ) . At the time of this analysis, 156 tumors had progressed. The unadjusted analysis showed that there was no statistically signifi cant difference between the two arms with respect to PFS ( P = .16). The 5-year PFS was 52.1% for the radiotherapy arm and 60.2% for the CRT arm. The difference in PFS reached borderline statistical signifi cance in the Cox regression analysis adjusted for T stage and overall stage (HR = 0.74 [95% confi dence interval {CI} = 0.54 to 1.0], P = .06, Supplementary Fig. 1 , which can be viewed at http:// jncicancerspectrum.oupjournals.org/jnci/ content/vol97/issue7 ). Subgroup analysis demonstrated that there was no statistically signifi cant difference in PFS between the arms for T1/T2 stage (HR = 0.99 [95% CI= 0.66 to 1.5], P = .97), whereas there was a statistically significant difference between the arms for T3/ T4 stage (HR = 0.53 [95% CI = 0.33 to 0.88], P = .012, Supplementary Fig. 2 , which can be viewed at http://jncicancer spectrum.oupjournals.org/jnci/content / vol97/issue7 ) favoring the CRT arm. At the time of this analysis, 133 deaths had been reported. The unadjusted analysis shows a borderline statistically significant difference in OS in favor of the concurrent arm ( P = .065). The 5-year OS was 58.6% (95% CI = 50.9% to 66.2%) for RT and 70.3% (95% CI = 63.4% to 77.3%) for CRT. In the Cox regression analysis, the difference in OS was statistically signifi cantly in favor of CRT after adjusting for T stage, age, and overall stage (HR = 0.71 [95% CI = 0.5 to 1.0]; P = .049, Fig. 2 ). Subgroup analysis demonstrated that there was no difference between OS in the arms for T1/T2 stage (HR = 0.93 [95% CI = 0.59 to 1.4]; P = .74), whereas there was a difference between the arms for T3/T4 stage (HR = 0.51 [95% CI = 0.3 to 0.88]; P = .013, Fig. 3 ), favoring the CRT arm. No statistically signifi cant difference in locoregional recurrence between the arms was observed, although there was a clear trend favoring the CRT arm for the T3/T4 stage subgroup (HR = 0.45 [95% CI = 0.21 to 1.0]; P = .051, Supplementary Fig. 3 , which can be viewed at http:// jncicancerspectrum.oupjournals.org/jnci/ content/vol97/issue7 . No statistically signifi cant difference in occurrence of distant metastases was observed between the arms (HR = 0.65 [95% CI = 0.37 to 1.2]; P = .15, Supplementary Fig. 4 , which can be viewed at http://jncicancerspectrum. oupjournals.org/jnci/content/vol97/issue7 ). At a median follow-up of 5.5 years, the improvement in OS demonstrated in this study confi rms that CRT should be used as standard treatment in locoregionally advanced endemic NPC. The relatively low toxicity and convenience of weekly outpatient cisplatin 40 mg/m 2 infusion make this regimen an attractive alternative to the high-dose cisplatin 100 mg/m 2 infusion every 3 weeks used in the United States Intergroup regimen. The modest dose of cisplatin given during radiotherapy may not be adequate to maximize the benefi t of chemotherapy in locoregionally advanced NPC, and the rate of local and distant failure may be further reduced by adding neoadjuvant or adjuvant chemotherapy. Patient tolerance to adjuvant chemotherapy is limited by the cumulative toxic effects of concurrent chemotherapy. Recent phase II studies using intensive neoadjuvant chemotherapy followed by concurrent cisplatin -radiotherapy have shown encouraging toxicity profi les and disease control ( 13 -15 ) .
